<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011062</url>
  </required_header>
  <id_info>
    <org_study_id>CDS01</org_study_id>
    <nct_id>NCT01011062</nct_id>
  </id_info>
  <brief_title>Effect of Angiotensin Receptor Blockade on Insulin Resistance and Adipose Tissue Cytokines in Type 2 Diabetes</brief_title>
  <official_title>Effect of Acute Angiotensin Receptor Blockade on Insulin Resistance and Selected Cytokines in Adipose Tissue in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the effect of acute angiotensin receptor blockade on insulin&#xD;
      action/insulin resistance and expressions of selected adipocytokines in subcutaneous adipose&#xD;
      tissue in insulin-resistant subjects with type 2 diabetes and healthy controls.&#xD;
&#xD;
      Hypothesis: Changes in adipocytokine concentrations and/or expressions and different&#xD;
      reactions to acute in vivo induced hyperinsulinemia and angiotensin receptor blockade will be&#xD;
      found in patients with type 2 diabetes compared to healthy subjects. A significant&#xD;
      relationships between insulin sensitivity and selected adipokines and intracellular fat&#xD;
      content and high energy phosphates in soleus muscle will be documented in healthy&#xD;
      individuals, while no significant relation will be found in patients with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      10-15 patients with type 2 diabetes and 10-15 healthy control subjects will be examined on an&#xD;
      outpatient basis. The following examination will be carried out in each subject after 12 hrs&#xD;
      fasting:&#xD;
&#xD;
        -  Oral glucose tolerance test (75 g of glucose) (in healthy subjects to confirm the normal&#xD;
           tolerance of glucose).&#xD;
&#xD;
        -  Evaluation of insulin secretion after 1 mg of glucagon i.v.&#xD;
&#xD;
        -  Hyperinsulinaemic (75 milly-international unit(mIU)/l) euglycemic clamp study lasting 4&#xD;
           hours combined with indirect calorimetry and biopsy of subcutaneous adipose tissue.&#xD;
&#xD;
        -  Hyperinsulinemic (75 mIU/l) euglycemic clamp study lasting 4 hours combined with&#xD;
           indirect calorimetry after losartan 100 mg given in the evening and in the morning&#xD;
           before the study.&#xD;
&#xD;
        -  Proton and phosphorus magnetic resonance spectroscopy.&#xD;
&#xD;
      Before (0 min), at 30 min and in the end of studies c) and d) the blood samples will be taken&#xD;
      and biopsies of subcutaneous abdominal adipose tissue will be done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity measured as glucose disposal during clamp</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma adipokines and their expressions in SAT</measure>
    <time_frame>at 0 and 240 min of the clamp</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Hyperinsulinaemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan + hyperinsulinaemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of Saline as a volume control intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperinsulinaemia</intervention_name>
    <description>Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp</description>
    <arm_group_label>Hyperinsulinaemia</arm_group_label>
    <arm_group_label>Losartan + hyperinsulinaemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Acute administration of losartan 200mg total prior to clamp</description>
    <arm_group_label>Losartan + hyperinsulinaemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Infusion of Saline as a volume control intervention</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 2 Diabetes treated with oral agents and/or diet&#xD;
&#xD;
          2. Healthy volunteers age- and sex-matched to type 2 diabetes, without any concomitant&#xD;
             disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 2 Diabetes&#xD;
&#xD;
               -  treated with insulin&#xD;
&#xD;
               -  clinical evidence of atherosclerotic complications&#xD;
&#xD;
               -  advanced long-term diabetic complications (manifest nephropathy, proliferative&#xD;
                  retinopathy)&#xD;
&#xD;
               -  other internal disease&#xD;
&#xD;
               -  weight change &gt;10% 3 months prior to study&#xD;
&#xD;
          2. Healthy volunteers&#xD;
&#xD;
               -  fulfilling the criteria of metabolic syndrome&#xD;
&#xD;
               -  weight change &gt;10% 3 months prior to study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terezie Pelikanova, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Center, Institute of Clinical and Experimental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Center, Institute of Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>October 17, 2013</last_update_submitted>
  <last_update_submitted_qc>October 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2013</last_update_posted>
  <responsible_party>
    <name_title>Dagmar KÃ¶veslygetyova</name_title>
    <organization>Diabetes Center, Institute for Clinical and Experimental Medicine</organization>
  </responsible_party>
  <keyword>Adipose tissue</keyword>
  <keyword>Adipokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

